Adaptimmune Therapeutics PLC — Director's Dealing 2016

Jan 4, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2016-01-01

Reporting Person: Laing Ian Michael (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares with a nominal value of GBP0.001 per share	29042800	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to purchase Ordinary Shares	$2.8379	2025-05-11	Ordinary Shares (159875)		Direct

Footnotes

F1: The exercise price was converted from GBP1.82 based on the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the date of grant. The actual exercise price will be the pounds sterling amount regardless of the exchange rate on the date of grant or of exercise.